TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:04
ARTELO BIOSCIENCES INC. ( ARTL ) https://www.artelobio.com
1.05USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-25.45%
ARTL
SPY
32.66%
-87.63%
ARTL
SPY
108.59%
-97.57%
ARTL
SPY
302.52%
ARTL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3.13
-1.61
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.34
0.00
0.49
-192.17
0.00
0.22
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.8704
-125.55
-48.05
1.78
Other Earnings and Cash Flow Stats:
ARTELO BIOSCIENCES INC. ( ARTL ) Net Income TTM ($MM) is -9.12
ARTELO BIOSCIENCES INC. ( ARTL ) Operating Income TTM ($MM) is -9.54
ARTELO BIOSCIENCES INC. ( ARTL ) Owners' Earnings Annual ($MM) is 0.00
ARTELO BIOSCIENCES INC. ( ARTL ) Current Price to Owners' Earnings ratio is 0.00
ARTELO BIOSCIENCES INC. ( ARTL ) EBITDA TTM ($MM) is -6.92
ARTELO BIOSCIENCES INC. ( ARTL ) EBITDA Margin is 0.00%
Capital Allocation:
ARTELO BIOSCIENCES INC. ( ARTL ) has paid 0.00 dividends per share and bought back -0.038741 million shares in the past 12 months
ARTELO BIOSCIENCES INC. ( ARTL ) has increased its debt by 0.06 million USD in the last 12 months
Capital Structure:
ARTELO BIOSCIENCES INC. ( ARTL ) Interest-bearing Debt ($MM) as of last quarter is 0
ARTELO BIOSCIENCES INC. ( ARTL ) Annual Working Capital Investments ($MM) are 4
ARTELO BIOSCIENCES INC. ( ARTL ) Book Value ($MM) as of last quarter is 6
ARTELO BIOSCIENCES INC. ( ARTL ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
ARTELO BIOSCIENCES INC. ( ARTL ) has 4 million in cash on hand as of last quarter
ARTELO BIOSCIENCES INC. ( ARTL ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ARTELO BIOSCIENCES INC. ( ARTL ) has 3 common shares outstanding as of last quarter
ARTELO BIOSCIENCES INC. ( ARTL ) has 0 million USD of preferred stock value
Academic Scores:
ARTELO BIOSCIENCES INC. ( ARTL ) Altman Z-Score is -9.41 as of last quarter
ARTELO BIOSCIENCES INC. ( ARTL ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
ARTELO BIOSCIENCES INC. ( ARTL ) largest shareholder is owning shares at 0.00 ($MM) value
Gregory D Gorgas(an insider) Bought 1200 shares of ARTELO BIOSCIENCES INC. ( ARTL ) for the amount of $4836.00 on 2022-08-11
0.83% of ARTELO BIOSCIENCES INC. ( ARTL ) is held by insiders, and 0.72% is held by institutions
ARTELO BIOSCIENCES INC. ( ARTL ) went public on 2017-11-14
Other ARTELO BIOSCIENCES INC. ( ARTL ) financial metrics:
FCF:-8.38
Unlevered Free Cash Flow:0.00
EPS:-1.40
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-71.18
Beta:1.78
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ARTELO BIOSCIENCES INC. ( ARTL ) :
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.